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Many neuropsychiatric drugs interact with more than one molecular target, and therapeutic indices
might be improved by prospectively designing compounds with proﬁles optimized against a combina-
tion of targets. The dibenzo-epine scaffold is considered a privileged structure, and this scaffold has been
explored rigorously in the search for potential novel neuropharmacologic treatments. Members of this
chemical class are known to interact with many receptors and transporters, particularly those of the
biogenic amine class. In this study, four points of diversity within a dibenzo-epine scaffold were varied
systematically and the pharmacologic proﬁles of the compounds were assessed across 14 receptors and
transporters thought to be important to clinical proﬁles of efﬁcacy and safety. The resulting data were
analyzed using a modiﬁed forward selection linear regression procedure, thus revealing potential
pharmacophoric relationships of the assessed targets within this chemical class. The results highlight a
strong covariance across numerous targets. Moreover, the outcome quantiﬁes the innately problematic
issue of prospectively designing compounds with deﬁned afﬁnities across multiple targets. Finally, an
exploration of the correspondence of binding afﬁnities to in vitro functional activity reveals an additional
layer of complexity central to prospectively designing compounds to engage multiple targets. The
apparent relatedness of the 5-HT2a and D2 activities suggests that the structural pharmacophores of
these receptors overlap more closely with each other than with members of their respective families.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
The initial discoveries of imipramine and clozapine, the foun-
dational neuropsychiatric drugs with tricyclic structures, spawned
decades of research aimed at designing novel therapies for psy-
chiatric disorders (Hippius, 1989). Consequently, dibenzo-epine
scaffolds were rigorously explored in search of novel neurophar-
macologic drugs. Indeed, many new chemotherapeutics were
brought to the marketplace based on the dibenzo-epine scaffold
and hence, it is considered to be a privileged structure. The advent
of receptor pharmacology revealed that members of this privileged(M.W. Wood), steven.
zowski@astrazeneca.com (D.
r Ltd. Open access under CC BY licensestructure can interact with a wide variety of targets, and that they
can inhibit biogenic amine receptors and transporters, in particular
(Coward, 1992). Recently, there has been renewed appreciation for
neuropsychiatric agents that engage multiple mechanisms. In fact,
it has been hypothesized that complex neuropsychiatric disorders
may only be optimally treated by drugs that engage multiple nodes
within networked systems (Roth et al., 2004).
A fundamental challenge in designing individual small mole-
cules that selectively engage multiple targets in a network is the
concurrent need to avoid engaging undesired targets. The single
agent, multi-target approach presupposes that the pharmacophoric
requirements of the desired targets are distinct enough from those
of undesired targets that adequate separation of the corresponding
afﬁnities can be achieved (Xie et al., 2012). The vast and varied
clinical success realized with members of the dibenzo-epine scaf-
fold implies that this class of compounds is well suited to exploring
the pharmacophoric interdependencies of a subset of key receptors
and transporters. A collection of twenty-four compounds from this
class, systematically varied across four points of differentiation,
were evaluated at fourteen receptors and transporters. The set.
M.W. Wood et al. / Neuropharmacology 77 (2014) 475e480476contained ﬁve approved neuropsychiatric drugs and several active
drug metabolites. The attendant pharmacophoric relationships of
the test set were evaluated using a straightforward statistical
method. The results quantify the covariate nature of the receptor
afﬁnities within the compound subset, producing models that
explain considerable variance and reveal unexpected relationships.
2. Materials and methods
2.1. Compounds
Compounds 1 (CAS#5747-48-8), 2 (1977-09-9), 3 (5747-63-7), 4 (2058-52-8), 5
(858670-47-0), 6 (5747-55-7), 7 (21636-40-8), 8 (2058-53-9), 9 (14028-44-5), 10
(27833-64-3), 11 (179418-95-2), 12 (3527-47-7), 13 (56296-18-5), 14 (1977-07-7), 15
(858669-84-8), 16 (1977-08-8), 17 (6104-71-8), 18 (5786-21-0), 19 (5001-00-3), 20
(1977-11-3), 21 (138246-83-0), 22 (1977-12-4), 23 (858670-48-1), and 24 (5542-88-
1) were synthesized at AstraZeneca Pharmaceuticals, LP (Wilmington, DE) or Adesis,
Inc. (New Castle, DE). All chemical structures were veriﬁed, and each has a purity of
>95%.
2.2. Radioligand binding
Radioligand binding was performed on membranes prepared from stably
transfected cells expressing human recombinant receptors or transporters. Radio-
ligand binding at dopamine (catalog #220320, DAT), norepineprine (#204410, NET),
and serotonin (#274030, SET) transporters was evaluated according to standard
validated protocols under conditions deﬁned by the contractor (Ricerca Biosciences,
Concord, OH, USA; http://www.ricerca.com). Compounds were evaluated in dupli-
cate across eight, half-log concentrations (0.3e300 mM). Radioligand binding at
adrenergic a1a (catalog #FAST-005B), serotonin 5-HT1a (#FAST-0500B), serotonin 5-
HT2a (#FAST-0505B), serotonin 5-HT2b (#FAST-0506B), serotonin 5-HT2c (#FAST-
507B), dopamine D1 (#FAST-0100B), dopamine D2 (#FAST-0101B), dopamine D3
(#ES-0173B), histamine H1 (#FAST-0170B), muscarinic M1 (#FAST-0260B) and M3
(#ES-212B) receptors was evaluated according to standard validated protocols under
conditions deﬁned by the contractor (Euroscreen, Gosselies, Belgium; http://www.
euroscreen.com). Compounds were ﬁrst evaluated at 0.1 nM, 10 nM, and 1 mM to
establish approximate IC50 values. Compounds were then evaluated in duplicate
across ten concentrations bracketing the approximate IC50. Reference standards
were run as an integral part of all assays to verify results.
2.3. In vitro functional assessment
In vitro functional assessment was performed on preparations of stably trans-
fected cells expressing human recombinant receptors or transporters. Uptake in-
hibition at dopamine (catalog #316000), norepineprine (#302000), and serotonin
(#364000) transporters was evaluated according to standard validated protocols
under conditions deﬁned by the contractor (Ricerca Biosciences, Concord, OH, USA;
http://www.ricerca.com). Compounds were evaluated in duplicate across ﬁve
concentrations (3, 30, & 300 nM, and 3 & 30 mM). Compounds were tested at
adrenergic a1a (catalog #FAST-005A), serotonin 5-HT1a (#FAST-0500A), serotonin
5-HT2a (#FAST-0505A), serotonin 5-HT2b (#FAST-0506A), serotonin 5-HT2c (#FAST-
507A), dopamine D2 (#FAST-0101A), histamine H1 (#FAST-0170A), muscarinic M1
(#FAST-0260A) and M3 (#ES-212A) receptors in an aequorin assay format and at
dopamine D3 (ES-0173G) in a GTPgS assay format according to standard validated
protocols under conditions deﬁned by the contractor (Euroscreen, Gosselies,
Belgium; http://www.euroscreen.com). Compounds were ﬁrst evaluated in dupli-
cate at 0.1 nM, 10 nM, and 1 mM for agonist activity and 0.05 nM, 5 nM, and 500 nM
for antagonist activity to establish approximate EC50 or IC50 values. Compounds
were tested at dopamine D1 (#FAST-0100C) in a cAMP format. Compounds were
ﬁrst evaluated in duplicate at 0.1 nM, 10 nM, and 1 mM for agonist activity and
antagonist activity to establish approximate EC50 or IC50 values. Compounds were
then evaluated in duplicate across ten concentrations bracketing the approximate
IC50. Measurable agonist activity was detected in very few instances. Compounds 1,
2, 3, 5, 7, 9, 11, 17, & 18 were also evaluated for agonist activity at 5-HT1a in a GTPgS
format, and compounds 1, 2, 5, 7, 11, 17, & 18 were also evaluated for agonist activity
at M1 in a FLIPR assay format (n ¼ 2 to 17 for each value, see supplemental
methods). Reference standards were run as an integral part of all assays to verify
results.
3. Calculation
3.1. For radioligand binding
For radioligand binding, all data were normalized to the
control responses and non-linear regression curves ﬁtted to them
using logistic ﬁts in GraphPad Prism 4.0 software (LaJolla, CA).
The best curve ﬁt of three parameter (i.e., nH ¼ 1) or fourparameter models (i.e., variable nH) was determined by com-
parison using the F-test. For ﬁts that did not converge, a two
parameter model was attempted (i.e., bottom constrained to 0);
13 of 336 (or 3.8%) radioligand binding pKi values were deter-
mined with two parameter ﬁts. Fits with pKi SEMs in excess 0.5
were rejected. The upper limit value (i.e., pKi < 5.0) is reported
for data not meeting the described criteria (4 of 336). An esti-
mated pKi of 3.5 was used as a value for the four unﬁtted sets (i.e.,
compound 13 at D1, D2, M1, & M3) in subsequent correlation
analyses.
3.2. For functional inhibition data
For functional inhibition data (i.e., antagonism), the best curve
ﬁt of three parameter (i.e., nH ¼ 1) or four parameter models (i.e.,
variable nH) was determined by comparison using the F-test. For
ﬁts that did not converge, ﬁts with pIC50 SEMs in excess of 0.5, or
ﬁts with less than 80% inhibition, the maximal inhibition at a
speciﬁed concentration is reported. Only calculated pIC50s were
used in correlation analysis. For functional activation data (i.e.,
agonism), a three parameter ﬁt was attempted. For ﬁts that did not
converge, ﬁts with pEC50 SEMs greater than 0.5, maximal activation
at a speciﬁed concentration is reported. Upper limit pEC50s are
reported for M1 FLIPR results.
3.3. Forward selection analyses
Forward selection analyses were developed using SigmaPlot
for Windows v11 (Systat Software, Inc., San Jose, CA). A global
ANOVA was performed with all sets of receptor pKis to establish
statistical validity of subsequent multiple comparisons. Next,
each dependent variable (i.e., pKi at Receptor Y) was regressed
across all independent variables (i.e., pKis at Receptors X1, X2, .
Xk, Xj,. Xn). Following univariate analysis, a modiﬁed Forward
Selection procedure similar to that described by Blanchet et al.,
was then used to build models of explained variance (Blanchet
et al., 2008). The independent variable with the highest signiﬁ-
cant correlation in univariate regression (e.g., Receptor Y vs. Re-
ceptor Xk) was assigned as the primary variable. The data were
regressed again using the identiﬁed independent variable (i.e.,
Receptor Xk) as the primary variable and all remaining variables
as secondary independent variables (i.e., pKis at Receptors X1, X2,
. Xj, Xl, . Xn). The second independent variable with highest
signiﬁcant correlation (e.g., Receptor Y vs. Receptor Xk and Re-
ceptor Xj) was identiﬁed and the procedure was repeated until
no additional signiﬁcant model improvement was realized.
As described by Blanchet et al., stopping criteria for model
improvement includes both alpha signiﬁcance and an improve-
ment in the adjusted coefﬁcient for multiple determination
(R2adj). Each ﬁnal model was then evaluated using leave-one-out
cross-validation (LOOCV), a cross-validation method reported to
exhibit minimal bias with small data sets (Molinaro et al., 2005).
Mean-squared errors (MSE) were all below 0.01. All p-values
were below 0.005 with the singular exception of the H1 model
missing compound 13 (p > 0.3), implying that the H1 model may
not be robust.
4. Results
The collection of 24 compounds contains ﬁve registered drugs,
including three antipsychotics [i.e., clothiapine (4), clozapine (18),
and loxapine (10)], an antidepressant (amoxapine, 9), and a hyp-
notic (perlapine, 20). The subset also contains three known drug
metabolites [i.e., norclozapine (17), norperlapine (19), and nor-
quetiapine (1)]. All of the compounds have been described in patent
Table 1
Radioligand binding afﬁnities (normal font) and functional potencies (italics) of all test compounds. The chemical structures of compounds 1 through 24 are described by the








Cmpd R1 R2 R3 X 5-HT1A 5-HT2A 5-HT2B 5-HT2C a1A D1 D2 D3 H1 M1 M3 NET DAT SET
1 H H H S 7.51 7.62 7.91 7.01 7.03 6.06 6.02 6.44 9.90 6.68 6.66 7.23 4.60 4.87
6.33 8.99 7.94 7.94 7.30 3.26 6.41 6.05 8.56 7.93 4.50 8.00 4.73 5.16
2 Me H H S 6.96 7.12 6.93 6.44 7.09 6.40 5.76 6.87 8.74 7.11 6.95 6.44 4.02 4.17
5.27 8.37 6.54 6.59 6.98 4.45 6.42 6.04 8.53 8.32 7.70 7.41 4.19 4.41
3 H Cl H S 5.65 8.29 7.47 7.60 8.05 6.61 7.59 7.48 8.70 5.40 5.13 6.66 5.50 5.36
5.68 9.12 8.30 8.06 7.61 4.84 8.20 6.57 8.10 6.82 6.19 7.70 5.42 5.32
4 Me Cl H S 5.42 8.72 7.46 7.40 7.96 7.14 8.15 8.83 8.89 6.09 6.00 6.15 5.23 4.65
5.41 9.06 7.95 8.29 8.39 5.26 8.78 7.30 8.61 7.54 6.72 7.26 5.51 5.03
5 H H Cl S 7.03 7.27 8.21 7.77 7.28 5.93 6.39 7.08 8.48 6.95 6.50 6.15 5.51 5.98
6.54 8.77 8.94 8.33 7.64 4.15 7.21 5.94 8.18 8.47 6.56 6.36 5.03 5.96
6 Me H Cl S 6.79 7.29 8.05 7.51 7.64 6.40 6.33 6.76 8.84 6.01 7.04 5.99 5.26 5.35
5.98 8.62 8.60 8.05 8.35 4.13 6.95 6.08 8.35 9.05 7.40 6.10 4.89 5.53
7 H H H O 7.44 7.62 7.78 6.86 6.47 5.59 5.80 6.23 8.43 4.86 5.28 6.84 3.75 4.67
6.01 8.72 8.35 7.76 6.20 4.50 7.07 6.27 8.21 6.85 5.62 7.36 3.69 4.43
8 Me H H O 6.89 7.15 7.41 6.65 7.06 6.19 5.96 6.20 9.10 5.82 5.57 5.76 3.78 3.46
5.54 8.12 7.46 7.12 6.93 3.96 6.34 6.07 9.15 6.94 6.22 6.94 3.43 3.70
9 H Cl H O 6.09 8.55 7.52 8.02 7.36 6.87 7.24 7.24 8.40 5.33 5.23 7.34 5.06 6.38
5.26 9.72 8.11 8.64 6.81 4.70 8.10 6.78 8.57 6.38 5.85 8.00 4.92 6.02
10 Me Cl H O 5.50 8.19 7.13 7.48 6.96 6.90 7.58 7.56 9.01 5.76 5.74 5.96 4.42 4.52
4.74 9.41 8.15 8.42 7.76 4.69 8.52 7.00 8.54 6.85 6.12 6.87 4.70 4.91
11 H H Cl O 7.36 7.86 8.15 8.25 7.59 6.66 6.90 7.00 8.89 5.77 5.50 6.52 5.12 5.90
6.82 9.69 9.26 9.08 7.75 4.67 7.34 5.91 8.83 6.98 6.60 6.53 4.47 5.81
12 Me H Cl O 6.73 7.59 7.70 7.48 7.91 6.49 6.88 7.09 9.07 6.44 6.03 5.57 4.69 4.89
5.65 9.00 8.69 8.19 8.56 4.56 7.67 5.98 8.97 7.68 6.86 6.18 4.28 4.99
13 H H H NH 4.80 5.08 5.79 5.18 5.76 3.50 3.50 4.22 6.16 3.50 3.50 4.24 3.56 3.39
4.13 6.64 5.94 5.96 4.38 4.50 4.50 4.50 6.60 4.80 4.50 5.38 4.50 4.50
14 Me H H NH 6.38 7.01 7.14 6.72 6.71 5.97 5.23 5.64 9.27 6.44 5.98 4.68 4.04 3.49
5.40 8.14 7.24 7.35 6.49 4.17 5.65 5.86 8.73 7.30 6.36 6.05 3.64 4.50
15 H Cl H NH 5.66 8.06 7.85 7.94 7.06 6.63 7.34 6.94 7.34 6.31 6.00 6.42 4.94 5.73
5.24 9.60 8.53 8.53 6.83 4.75 8.11 6.49 8.23 7.23 6.66 7.26 4.68 5.60
16 Me Cl H NH 5.14 8.07 7.49 7.61 7.32 7.13 7.23 7.16 8.66 6.88 6.57 5.00 4.60 4.83
4.50 9.11 8.17 8.21 6.84 5.14 8.42 6.83 8.72 8.26 7.03 7.04 4.54 5.40
17 H H Cl NH 7.39 7.55 7.77 7.75 7.20 6.45 6.37 6.72 8.76 6.62 6.31 5.96 4.72 5.83
6.26 9.01 8.85 8.27 7.18 4.48 6.82 5.26 8.56 7.71 6.38 5.40 4.15 5.54
18 Me H Cl NH 6.98 7.90 7.98 7.33 7.85 6.86 6.65 6.67 8.97 7.09 6.58 5.24 4.43 5.19
5.43 9.19 8.66 8.01 8.65 4.70 6.97 5.86 9.02 8.47 7.12 6.09 4.39 5.59
19 H H H CH2 7.01 7.14 7.47 7.22 6.55 5.88 5.07 5.73 8.65 5.77 5.74 6.44 3.96 4.11
5.77 8.19 7.55 7.81 6.23 4.06 6.06 5.57 8.38 6.61 6.41 7.04 4.62 4.35
20 Me H H CH2 6.61 7.15 7.23 6.89 6.65 6.47 5.61 6.46 8.89 6.45 6.16 5.81 3.99 4.24
5.01 8.07 6.95 7.03 6.17 4.45 5.98 6.07 8.73 7.60 6.77 6.95 3.79 4.40
21 H Cl H CH2 6.09 8.07 7.21 9.09 7.30 7.02 7.34 7.36 8.60 5.54 5.57 6.74 5.15 5.16
5.32 9.29 6.62 8.15 7.03 5.07 10.17 6.81 8.27 6.59 6.15 7.57 5.17 4.97
22 Me Cl H CH2 5.24 8.43 8.01 7.75 7.47 7.42 7.51 8.05 8.82 6.10 5.82 5.75 4.67 5.11
5.30 9.08 8.24 8.64 7.53 5.39 8.38 7.02 8.53 7.19 6.50 6.69 4.94 5.31
23 H H Cl CH2 7.10 7.21 8.43 9.22 7.29 6.21 6.52 6.85 8.57 6.19 5.91 6.10 5.23 6.17
6.34 8.98 8.77 8.45 7.36 4.68 6.98 5.50 8.10 7.81 6.93 6.63 4.97 5.97
24 Me H Cl CH2 6.36 7.63 8.33 7.85 8.34 6.57 6.43 6.50 8.64 7.13 6.42 5.45 4.56 6.59
5.63 8.76 8.53 8.30 7.84 4.45 6.71 6.04 8.38 8.53 7.44 6.12 3.69 5.83
M.W. Wood et al. / Neuropharmacology 77 (2014) 475e480 477applications, although the synthesis of compound 21 has never
been reported. Surprisingly, no peer-reviewed biological data have
been reported with compounds 5, 13, 15, 21, or 23 (Burki et al., 1977,
1978; Grimm et al., 2006; Kalhapure et al., 2011; Schmutz, 1975;
Smits et al., 2006; Warawa et al., 2001).
All 24 compounds were evaluated for inhibition of radioligand
binding across 11 GPCRs and three biogenic amine transporters (see
Table 1). pKis could be calculated from the raw data for 332 of the336 tests. Binding afﬁnities expressed as pKis range from 3.4 to 9.9
across all targets, with the average afﬁnity at H1 being the highest
and the average afﬁnity at DAT being the lowest. Compound 13 is
the least potent across all targets.
All 24 compounds were also evaluated for antagonist activity
across 11 GPCRs and for uptake inhibition at three biogenic amine
transporters (Table 2). Half maximal inhibitory concentrations
(IC50) could be calculated from the raw data for 281 of the 336 tests.
Table 3
Correlations of binding (x) vs. function (y) values. The adjusted coefﬁcient of
determination (R2adj) and p-value for parametric analysis (linear regression) and the
Spearman rank coefﬁcient (Rs) and p-value for non-parametric (Spearman) analysis
are shown for the comparison of pIC50s vs. pKis for each receptor.
Linear regression Spearman
R2adj p-value Rs p-value
a1a 65% <0.0001 76% <0.0001
5HT1a 58% <0.001 80% <0.001
5HT2a 78% <0.0001 85% <0.0001
5HT2b 72% <0.0001 82% <0.0001
5HT2c 66% <0.0001 87% <0.0001
D1 65% <0.001 77% <0.005
D2 77% <0.0001 92% <0.0001
D3 59% <0.0001 70% <0.0005
H1 65% <0.0001 75% <0.0001
M1 60% <0.0001 85% <0.0001
M3 71% <0.0001 82% <0.0001
NET 57% <0.0001 74% <0.0001
DAT 43% <0.05 64% NS
SET 73% <0.0001 88% <0.0001
M.W. Wood et al. / Neuropharmacology 77 (2014) 475e480478Negative log IC50s (pIC50s) range from 4.3 to 10.2 across all targets,
with the average afﬁnity at 5-HT2a being the highest and average
afﬁnity at DAT being the lowest. Compound 13 is the least potent
across all targets.
The relationships between binding afﬁnities and inhibitory
concentrations were evaluated across the fourteen targets using
both parametric linear regression and non-parametric rank order
(i.e., Spearman correlation) tests (Table 3). The relationship be-
tween binding afﬁnities and inhibitory concentrations was identi-
ﬁed as both linear and monotonic for thirteen of the fourteen
targets. Only the non-parametric test for DAT failed to achieve
signiﬁcance, perhaps due to the generally poor potency and the
limited number of calculated inhibitory concentrations. From the
analyses, it can be inferred that binding afﬁnities are a suitable
surrogate for functional inhibition within this chemical class and
across the targets examined.
To investigate the correlative relationships across the given
targets, simple linear regression comparisons were performed
serially across all permutations using the radioligand binding af-
ﬁnity data (Table 4). Approximately two-thirds of all comparisons
are signiﬁcant (i.e., p < 0.05), and more than 40% were strongly
signiﬁcant (p < 0.01) suggesting that the afﬁnities at the targets
examined are widely interrelated. Many of the covariate relation-
ships might be expected based on known pharmacologic relation-
ships (e.g., 82% correlation between the muscarinic family
members, M1 and M3). However, strong correlations exist which
span receptor families (e.g., 80% correlation between D1 and 5-
HT2a).
To ascertain the extent of binding afﬁnity variance at each target
that could be explained by the afﬁnity at all other targets, a
modiﬁed forward selection procedure was employed (Blanchet).
The procedure produces models which explain between 41% and
96% of the variance at each target. In most cases, two independent
variables account for most of the explained variance.
All 24 compounds were also evaluated for agonist activity across
the 11 GPCRs (Table 6). Only eight instances of measurable agonism
were detected across the 264 evaluations. The ﬁndings from the
initial agonist screen do not agree completely with previous reportsTable 2
Functional inhibition of all test compounds. Half-maximal inhibitory concentrations at tes
cannot be calculated, the maximum inhibition is expressed as a percentage in parenthesis.
y ¼ 30 mM (for transporters) or 31.6 mM (GPCRs).
Cmpd 5HT2c 5HT2b 5HT2a 5HT1a a1a D1 D2
1 7.9 7.9 9.0 6.3 7.3 (4%)y 6.4
2 6.6 6.5 8.4 (52%)* 7.0 (15%)y 6.4
3 8.1 8.3 9.1 5.7 7.6 4.8 8.2
4 8.3 8.0 9.1 5.4 8.4 5.3 8.8
5 8.3 8.9 8.8 6.5 7.6 (20%)y 7.2
6 8.0 8.6 8.6 6.0 8.4 (22%)y 6.9
7 7.8 8.4 8.7 6.0 6.2 (4%)y 7.1
8 7.1 7.5 8.1 (72%)* 6.9 (15%)y 6.3
9 8.6 8.1 9.7 5.3 6.8 4.7 8.1
10 8.4 8.2 9.4 (31%)* 7.8 4.7 8.5
11 9.1 9.3 9.7 6.8 7.8 4.7 7.3
12 8.2 8.7 9.0 5.7 8.6 4.6 7.7
13 6.0 5.9 6.6 (15%)* (11%)y (0%)y (14%
14 7.3 7.2 8.1 (59%)* 6.5 (21%)y 5.7
15 8.5 8.5 9.6 (56%)* 6.8 4.7 8.1
16 8.2 8.2 9.1 (21%)* 6.8 5.1 8.4
17 8.3 8.9 9.0 6.3 7.2 (48%)y 6.8
18 8.0 8.7 9.2 (65%)* 8.7 4.7 7.0
19 7.8 7.6 8.2 5.8 6.2 (11%)y 6.1
20 7.0 6.9 8.1 (43%)* 6.2 (45%)y 6.0
21 8.2 6.6 9.3 5.3 7.0 5.1 10.2
22 8.6 8.2 9.1 (32%)* 7.5 5.4 8.4
23 8.5 8.8 9.0 6.3 7.4 4.7 7.0
24 8.3 8.5 8.8 5.6 7.8 (46%)y 6.7(Jensen et al., 2008; Sur et al., 2003). A subset of the compounds
were evaluated for agonism at 5-HT1a and M1 in alternative for-
mats. The data resulting from evaluation in the alternative assay
formats is similar to those already reported.
5. Discussion
The identiﬁcation of small molecules as potential therapeutics
with exquisite selectivity for a single target has become a routine
mode of operation in the ﬁeld of drug discovery. However, chal-
lenges to this paradigm and arguments for multifunctional thera-
peutics have recently emerged (Hopkins, 2008). Multifunctional
agents have been known and used the ﬁeld of neuropharmacology
for many years. In this study, a collection of twenty-four com-
pounds, many known to exhibit multifunctional properties, were
selected and evaluated for binding afﬁnity and functional response
across a set of fourteen targets. Many of the members of thet receptors are expressed as inverse log transforms (pIC50’s). In instances where IC50’s
The concentrations at maximum inhibition are denoted as *¼ 5 mM, #¼ 15.8 mM, and
D3 H1 M1 M3 NET DAT SET
6.0 8.6 7.9 (15%)# 7.8 4.7 5.2
6.0 8.5 8.3 7.7 7.4 (30%)y (39%)y
6.6 8.1 6.8 6.2 7.7 5.4 5.3
7.3 8.6 7.5 6.7 7.3 5.5 5.0
5.9 8.2 8.5 6.6 6.4 5.0 6.0
6.1 8.4 9.0 7.4 6.1 (84%)y 5.5
(64%)y 8.2 6.8 5.6 7.4 (17%)y (50%)y
6.1 9.2 6.9 6.2 6.8 (8%)y (3%)y
6.8 8.6 6.4 5.9 8.0 (73%)y 6.0
7.0 8.5 6.8 6.1 6.9 (64%)y (72%)y
5.9 8.8 7.0 6.6 6.5 (43%)y 5.8
6.0 9.0 7.7 6.9 6.2 4.3 (81%)y
)# (11%)y 6.6 (55%)y (23%)# (32%)y (5%)y (0%)y
5.9 8.7 7.3 6.4 6.1 (10%)y (7%)y
6.5 8.2 7.2 6.7 7.3 4.7 5.6
6.8 8.7 8.3 7.0 7.0 (56%)y 5.4
5.3 8.6 7.7 6.4 6.6 (32%)y 5.5
5.9 9.0 8.5 7.1 6.1 (44%)y 5.6
5.6 8.4 6.6 6.4 7.0 (27%)y (38%)y
6.1 8.7 7.6 6.8 6.9 (15%)y (45%)y
6.8 8.3 6.6 6.2 7.6 5.2 5.0
7.0 8.5 7.2 6.5 6.7 4.9 5.3
5.8 8.1 7.8 6.9 6.6 (48%)y 6.0
6.0 8.4 8.5 7.4 6.1 (20%)y 5.8
Table 4
Simple linear regression comparisons of receptor pKis. The adjusted coefﬁcient of determination (R2adj) for each pair of statistically signiﬁcant (i.e., p < 0.05 and p < 0.01 in
bold) pKi comparisons is displayed in the corresponding cell. Blank cells represent comparisons that do not reach signiﬁcance.




5HT2b 36% 21% 21%
5HT2c 27% 35% 43%
D1 46% 80% 23% 39%
D2 51% 87% 19% 45% 75%
D3 45% 77% 15% 32% 72% 88%
H1 15% 20% 19% 18% 31% 13%
M1 24% 28% 30% 33%
M3 18% 14% 29% 28% 38% 82%
DAT 43% 30% 28% 55% 23% 49% 44%
NET 23% 15% 14%
SET 36% 20% 53% 56% 15% 26% 16% 54% 13%
Table 5
Results of modiﬁed forward selection linear regression. The detailed outcome of the modiﬁed forward selection procedure is presented for each receptor. Total explained
variance (i.e., R2adj for the ﬁnal model) is displayed parenthetically in the ﬁrst column, with the degree of explained variance attributable to each independent variable (i.e.,
receptor) displayed parenthetically in the adjacent cells.
Receptor modeled, dependent variable









a1a (63%) D2 (53%) 5-HT2b (10%)
5-HT1a (79%) D2 (28%) 5-HT2b (24%) H1 (15%) NET (12%)
5-HT2a (94%) D2 (87%) D1 (3%) NET (3%) DAT (1%)
5-HT2b (74%) SET (55%) H1 (19%)
5-HT2c (70%) SET (58%) D1 (12%)
D1 (89%) 5-HT2a (81%) M1 (8%)
D2 (96%) D3 (89%) 5-HT2a (5%) DAT (1%) NET (1%)
D3 (89%) D2 (89%)
H1 (41%) M3 (41%)
M1 (83%) M3 (83%)
M3 (83%) M1 (83%)
NET (63%) 5-HT2a (27%) 5-HT1a (20%) M1 (16%)
DAT (67%) 5-HT2c (57%) a1a (10%)
SET (58%) 5-HT2c (58%)
M.W. Wood et al. / Neuropharmacology 77 (2014) 475e480 479collection have been evaluated extensively, occasionally in direct
comparison with other members (Schmutz, 1975). The collection
examined here includes ﬁve approved neuropsychiatric drugs.
Surprisingly, there is an equal number of compounds in the
collection for which no biological data have been published in peer-
reviewed studies. The comprehensive evaluation of the deﬁned
subset of compounds from the privileged chemical space reported
here highlights a fundamental issue in prospectively designingTable 6
Functional agonism of all test compounds. Half-maximal effective concentrations at test r
cannot be calculated, the maximum activation is expressed as a percentage in parenthesis
y ¼ 31.6 mM. All values represent means of independent evaluations (n ¼ 2e17). NT deno
Cmpd. # 5HT1a (GTPgS) M1 (FLIPR) 5HT2a (aequorin) 5HT2b
pEC50 Emax pEC50 Emax pEC50 Emax pEC50
1 5.5 90% <4.4 e
2 5.9 66% <4.4 e
3 NT <4.4 e
4 NT NT e
5 6.3 40% <4.4 e e (32%)*
7 6.1 77% 5.27 24%
9 NT <4.4 e
11 6.7 62% 5.97 55%
13 NT NT
17 6.5 67% 6.88 84%
18 6 48% <4.0 e
20 e (56%)# NT
23 NT NTmultifunctional molecules; concurrently designing away from un-
desired pharmacologic interactions is non-trivial.
A modiﬁed forward selection linear regression was used to
quantify the explained variance of binding afﬁnities at individual
targets as a function of binding afﬁnities at all other targets
(Table 5). It can be inferred from the models developed by the
described procedure that the pharmacophoric requirements of
certain targets overlap considerably. One particularly interestingeceptors are expressed as inverse log transforms (pEC50’s). In instances where EC50’s
. The concentrations at maximum inhibition are denoted as * ¼ 1 mM, # ¼ 20 mM, and
tes not tested.
(aequorin) D2 (aequorin) D3 (aequorin) M1 (aequorin)




6.5 30% 5.6 121%
e (14%)y
M.W. Wood et al. / Neuropharmacology 77 (2014) 475e480480ﬁnding is the apparent relatedness of the 5-HT2a and D2 activities
that suggests overlapping structural pharmacophores. Overall, 94%
of the variance of 5-HT2a binding afﬁnity is explained by the model.
The majority of the explained variance is attributable to D2 afﬁnity
alone. Moreover, serial univariate linear regression analysis
(Table 4) reveals that the afﬁnity at 5-HT2a correlates more closely
to the afﬁnities at each dopamine receptor examined than to the
afﬁnities at the other 5-HT2 receptors examined. This observation
would not be expected given the evolutionary relationships
predicted by nucleotide sequence comparisons. On the basis of
genetic phylogeny, 5-HT2a is much more closely related to 5-HT2c
than D2 (Cravchik and Goldman, 2000). It is not known whether
the observed 5-HT2a/D2 correlation will generalize to more
chemotypes.
Radioligand binding afﬁnities (pKis) correlated well with
antagonist half maximal inhibitory concentrations (pIC50s), sug-
gesting that the explained variance models developed using bind-
ing afﬁnities might also be expected to correspond to functional
antagonism. No attempt was made to correlate functional agonism,
but the paucity of agonist activity at the eleven receptors screened
suggests that agonism is less well predicted by binding afﬁnity. In a
few instances, the functional agonism detected did not correspond
fully with published reports (Heusler et al., 2011; Jensen et al.,
2008; Sur et al., 2003). Discrepancies could represent differential
sensitivity to receptor activation in the different assays.
6. Conclusion
The relatedness of the pharmacophores of a set of common
psychiatric targets was mapped with a straightforward, but novel
procedure using data generated with a collection of twenty-four
compounds from a privileged tricycle structure. The modiﬁed for-
ward selection analysis emphasizes the highly correlative nature of
relative afﬁnities across a number of targets within the chemical
space studied, and provides a means to quantify these relation-
ships. A fundamental challenge to the concept of prospectively
designing multifunctional molecules is the ability to achieve
speciﬁed afﬁnity criteria at more than one target while avoiding
unwanted interactions. If the principle outcome of the analysis
reported here can be applied broadly, it suggests that meeting the
challenge of designing multifunctional molecules may be a very
low probability event when the design criteria are both rigid and
numerous. As the generation of in vitro data continues to become
increasingly facile, large and homogenous data sets should emerge.
Themodiﬁed forward selection procedure employed heremay offera useful method for analyzing those large and homogenous data
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